Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 2,038.12 ($27.62) and traded as high as GBX 2,152 ($29.16). Hikma Pharmaceuticals shares last traded at GBX 2,148 ($29.11), with a volume of 286,072 shares changing hands.
Analyst Upgrades and Downgrades
HIK has been the subject of several recent research reports. JPMorgan Chase & Co. reiterated an "overweight" rating on shares of Hikma Pharmaceuticals in a report on Friday, March 7th. Berenberg Bank restated a "buy" rating and issued a GBX 2,560 ($34.69) price objective on shares of Hikma Pharmaceuticals in a research note on Monday, March 10th.
Get Our Latest Research Report on HIK
Hikma Pharmaceuticals Price Performance
The firm's fifty day simple moving average is GBX 1,969.65 and its 200 day simple moving average is GBX 2,040.33. The firm has a market cap of £5.83 billion, a P/E ratio of 20.63, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66.
Insider Transactions at Hikma Pharmaceuticals
In related news, insider Victoria Hull sold 2,777 shares of the business's stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of GBX 1,800 ($24.39), for a total transaction of £49,986 ($67,740.89). Also, insider Said Darwazah sold 13,863 shares of the business's stock in a transaction on Friday, May 30th. The stock was sold at an average price of GBX 2,138 ($28.97), for a total value of £296,390.94 ($401,668.17). Company insiders own 30.54% of the company's stock.
Hikma Pharmaceuticals Company Profile
(
Get Free Report)
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.
Read More
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
